Land: Irland
Språk: engelska
Källa: HPRA (Health Products Regulatory Authority)
PIMOZIDE
Janssen-Cilag Ltd
N05AG02
PIMOZIDE
4 Milligram
Tablets
Product subject to prescription which may be renewed (B)
Antipsychotics
Authorised
1993-03-31
PACKAGE LEAFLET: INFORMATION FOR THE USER ORAP ® 4 MG TABLETS Pimozide Orap is a registered trademark READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START USING THIS MEDICINE. Keep this leaflet. You may need to read it again If you have any further questions, ask your doctor, nurse or pharmacist This medicine has been prescribed for you. Do not pass it on to others. It may harm them, even if their symptoms are the same as yours If you get side effects and they become serious or if you notice any side effects not listed in this leaflet, please tell your doctor, nurse or pharmacist IN THIS LEAFLET 1 What Orap tablets are and what they are used for 2 Before you take Orap tablets 3 How to take Orap tablets 4 Possible side effects 5 How to store Orap tablets 6 Further information 1 WHAT ORAP TABLETS ARE AND WHAT THEY ARE USED FOR The name of your medicine is Orap 4 mg tablets. They are called ‘Orap tablets’ or just ‘Orap’ in this leaflet. Orap tablets contain a medicine called pimozide. This belongs to a group of medicines called ‘neuroleptics’. Orap tablets are used for illnesses affecting the way you think, feel or behave. These illnesses may make you: Feel confused See, hear or feel things that are not there (hallucinations) Believe things that are not true (delusions) Feel unusually suspicious (paranoia) Feel elated or over excited (mania) IMPORTANT - it may take some time before you feel the full effect of the medicine but it is important that you carry on taking it for as long as your doctor has told you. 2 BEFORE YOU TAKE Läs hela dokumentet
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Orap 4 mg Tablets 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains pimozide 4 mg For a full list of excipients, see section 6.1 3 PHARMACEUTICAL FORM Tablet. Round, pale green, biconvex tablets impressed with a cross-score on one face and ‘Janssen’ on the other face. The scoreline is only to facilitate breaking for ease of swallowing and not to divide into equal doses. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Orap is indicated in the management of chronic schizophrenia and allied psychoses, including monosymptomatic hypochondriacal psychosis, mania and hypomania. Orap is also indicated as an initial therapy in outpatients and in newly or re-admitted patients, provided agitation, aggressiveness, or severe anxiety do not constitute the predominant symptoms. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION For oral use. A single morning dose is recommended for all patients. Adults and children over 12 years of age only An ECG should be performed in all patients prior to treatment and in those patients receiving Orap in excess of 16 mg daily, regular periodic ECGs should be performed. Since individual response to antipsychotic drugs is variable, dosage should be individually determined and is best initiated and titrated under close clinical supervision. In determining the initial dose, consideration should be given to the patient’s age, severity of symptoms and previous response to other neuroleptic drugs. The patients should be reviewed regularly to ensure the minimum effective dose is being used. The recommended starting dose is 2 to 4 mg daily. Increases in dosage should be made at weekly intervals or longer, with 2-4 mg per day. The maintenance dose is usually in the range of Läs hela dokumentet